Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics

References

• Janga KY, Jukanti R, Velpula A, et al. Bioavailability enhancement of zaleplon via proliposomes: role of surface charge. Eur J Pharm Biopharm 2012;80:347–57
   PubMed Web of Science ®Google Scholar
• Xiao Y, Song Y, Chen Z, Ping Q. Preparation of silymarin proliposomes and its pharmacokinetics in rats. Yao xue xue bao = Acta Pharmacol Sin 2005;40:758–63
   PubMedGoogle Scholar
• Xu H, He L, Nie S, et al. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release 2009;140:61–8
   PubMed Web of Science ®Google Scholar
• Bobbala SKR, Veerareddy PR. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J Liposome Res 2012;22:285–94
   PubMed Web of Science ®Google Scholar
• Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation andin vitro evaluation using PAMPA, Caco–2 and rat intestine. Int J Pharm 2009;380:96–104
   PubMed Web of Science ®Google Scholar
• Katare O, Vyas S, Dixit V. Effervescent granule based proliposomes of ibuprofen. J Microencapsul J Microencapsul 1990;7:455–62
   PubMed Web of Science ®Google Scholar
• Katare O, Vyas S, Dixit V. Proliposomes of indomethacin for oral administration. J Microencapsul 1991;8:1–7
   PubMed Web of Science ®Google Scholar
• Potluri P, Betageri GV. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Deliv 2006;13:227–32
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Venkatesan N, Betageri GV. Proliposomes for oral delivery: progress and challenges. Curr Pharm Biotechnol 2014;16:303–12
   Web of Science ®Google Scholar
• Velpula A, Jukanti R, Janga KY, et al. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Dev Ind Pharm 2013;39:1895–906
   PubMed Web of Science ®Google Scholar
• Sheue Nee Ling S, Magosso E, Abdul Karim Khan N, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 2006;32:335–45
   PubMed Web of Science ®Google Scholar
• Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 2005;27:951–9
   PubMed Web of Science ®Google Scholar
• Criscione L, Bradley WA, Bühlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13:230–50
   Web of Science ®Google Scholar
• Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997;52:115–20
   PubMed Web of Science ®Google Scholar
• Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62:272–8
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharma Res 2005;22:11–23
   Web of Science ®Google Scholar
• Cappello B, Di Maio C, Iervolino M, Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-\ boldbeta-cyclodextrin. J Incl Phenom Macrocycl Chem 2006;54(3–4):289–94
   Web of Science ®Google Scholar
• Parmar B, Mandal S, Petkar K, et al. Valsartan loaded solid lipid nanoparticles: development, characterization, and in vitro and ex vivo evaluation. Int J Pharm Sci Nanotechnol 2011;4:1483–90
   Google Scholar
• Yan Y-D, Sung JH, Kim KK, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int J Pharma 2012;422:202–10
   PubMed Web of Science ®Google Scholar
• Tarur VR, Sathe DG, Rao N, et al. Process for the preparation of micronized valsartan. U.S. Patent Application 12/304,148; 2009
   Google Scholar
• Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech 2010;11:314–21
   PubMed Web of Science ®Google Scholar
• Gurrapu A, Jukanti R, Bobbala SR, et al. Improved oral delivery of valsartan from maltodextrin based proniosome powders. Adv Powder Technol 2012;23:583–90
   Web of Science ®Google Scholar
• Cao Q-R, Liu Y, Xu W-J, et al. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Int J Pharm 2012;434:325–33
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50:61–80
   PubMed Web of Science ®Google Scholar
• Chu C, Tong S-s, Xu Y, et al. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin 2011;32:973–80
   PubMed Web of Science ®Google Scholar
• Staniforth J, Aulton M. Pharmaceutics: the science dosage form design. Edinburgh, Scotland: Churchill Livingstone; 1988:610–36
   Google Scholar
• Galia E, Nicolaides E, Hörter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharma Res 1998;15:698–705
   Web of Science ®Google Scholar
• Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001;46:27–43
   PubMed Web of Science ®Google Scholar
• Augustijns PF, Bradshaw TP, Gan L-SL, et al. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem Biophys Res Commun 1993;197:360–5
   PubMed Web of Science ®Google Scholar
• Bermejo M, Avdeef A, Ruiz A, et al. PAMPA—a drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci 2004;21:429–41
   PubMed Web of Science ®Google Scholar
• Song K-H, Chung S-J, Shim C-K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 2005;106:298–308
   PubMed Web of Science ®Google Scholar
• Ravis WR, Feldman S. Effect of enzyme-inducing and enzyme-inhibiting agents on drug absorption I: 3-O-methylglucose transport in rats. J Pharma Sci 1978;67:245–8
   PubMed Web of Science ®Google Scholar
• Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999;13:154–68
   PubMed Web of Science ®Google Scholar
• Issa C, Gupta P, Bansal AK. Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: a technical note. AAPS PharmSciTech 2003;4:44–9
   Google Scholar
• Jukanti R, Mateti A, Bandari S, Veerareddy PR. Transdermal delivery of acyclovir sodium via carbopol gels: role of chemical permeation enhancers. Lett Drug Des Discov 2011;8:381–9
   Web of Science ®Google Scholar
• Tosco P, Rolando B, Fruttero R, et al. Physicochemical profiling of sartans: a detailed study of ionization constants and distribution coefficients. Helv Chim Acta 2008;91:468–82
   Web of Science ®Google Scholar
• Gregoriadis G, Davis C. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Commun 1979;89:1287–93
   PubMed Web of Science ®Google Scholar
• Betageri G. Liposomal encapsulation and stability of dideoxyinosine triphosphate. Drug Dev Ind Pharm 1993;19:531–9
   Web of Science ®Google Scholar
• Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001;1:923–47
   PubMed Web of Science ®Google Scholar
• Elorza M, Garcia de la Cruz F, San Juan R, et al. Linkages between macromolecules in Candida albicans cell wall. Arch Med Res 1992;24:305–10
   Google Scholar
• Dan N. Effect of liposome charge and PEG polymer layer thickness on cell–liposome electrostatic interactions. Biochim Biophys Acta 2002;1564:343–8
   PubMed Web of Science ®Google Scholar
• Dragicevic-Curic N, Gräfe S, Gitter B, et al. Surface charged temoporfin-loaded flexible vesicles: in vitro skin penetration studies and stability. Int J Pharm 2010;384:100–8
   PubMed Web of Science ®Google Scholar
• Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007;337:329–35
   PubMed Web of Science ®Google Scholar
• Rengel RG, Barišić K, Pavelić Ž, et al. High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur J Pharm Sci 2002;15:441–8
   PubMed Web of Science ®Google Scholar
• Staniforth J. Powder flow. In: Aulton ME, ed. Pharmaceutics: the science of dosage form design. 2nd ed. Edinburgh, Scotland: Churchill Livingstone; 2002:197–210
   Google Scholar
• Cócera M, López O, Coderch L, et al. Alterations in stratum corneum lipid liposomes due to the action of Triton X-100: influence of the level of ceramides on this process. J Control Release 2000;68:387–96
   PubMed Web of Science ®Google Scholar
• Du B, Li Y, Li X, Youmei A, et al. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int J Pharm 2010;384:140–7
   PubMed Web of Science ®Google Scholar
• Yanamandra S, Venkatesan N, Kadajji VG, et al. Proliposomes as a drug delivery system to decrease the hepatic first-pass metabolism: Case study using a model drug. Eur J Pharm Sci 2014;64:26–36
   PubMed Web of Science ®Google Scholar
• KV S, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm 2007;5:92–7
   PubMedGoogle Scholar
• Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998;41:1007–10
   PubMed Web of Science ®Google Scholar
• Kerns EH, Di L, Petusky S, et al. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci 2004;93:1440–53
   PubMed Web of Science ®Google Scholar
• Watanabe E, Takahashi M, Hayashi M. A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. Eur J Pharm Biopharm 2004;58:659–65
   PubMed Web of Science ®Google Scholar
• Palasciano G, Tytgat GN. Cell type-dependent effect of phospholipid and cholesterol on bile salt cytotoxicity. Gastroenterology 1991;101:457–64
   PubMed Web of Science ®Google Scholar
• Planas M, Gonzalez P, Rodriguez L, et al. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth Analg 1992;75:615–21
   PubMed Web of Science ®Google Scholar
• Cevc G, Schätzlein A, Gebauer D, Blume G. Ultra-high efficiency of drugs and peptide transfer through the intact skin by means of novel drug carriers, transfersomes. Cardiff, UK: STS Publishing; 1993
   Google Scholar
• Cevc G, Schätzlein A, Blume G. Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Release 1995;36:3–16
   Web of Science ®Google Scholar
• Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release 1994;29:253–67
   Web of Science ®Google Scholar
• Werner U, Kissel T, Reers M. Effects of permeation enhancers on the transport of a peptidomimetic thrombin inhibitor (CRC 220) in a human intestinal cell line (Caco-2). Pharm Res 1996;13:1219–27
   PubMed Web of Science ®Google Scholar
• Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Clin Pharmacol 2009;157:907–21
   Web of Science ®Google Scholar
• Waldmeier F, Flesch G, Mu Ller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59–71
   PubMed Web of Science ®Google Scholar
• Bissessor N, White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag 2007;3:425
   PubMedGoogle Scholar